Immutep
Immutep Ltd (formerly Prima Biomed) is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.
| Company type | Public |
|---|---|
| Nasdaq: IMMP ASX: IMM | |
| Industry | Biotechnology |
| Founded | 2001 |
| Headquarters | Sydney, Australia Leipzig, Germany |
Key people | Marc Voigt (CEO) Frédéric Triebel (Chief Scientific and Medical Officer) |
| Products | IMP321, GSK2831781, CVac LAG-3 Immunotherapy |
| Website | www |
Prima currently has three main products in its pipeline, all acquired with Immutep:
Eftilagimod alpha, (lab name: IMP321) which is recombinant soluble LAG-3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer.
IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline.
IMP701, an antagonist monoclonal antibody to LAG3 for use in cancer. This product has been licensed to Novartis